Four (4) each Genomic Sequencing Systems

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

RFQ-FDA-133845-133915

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6640

Additional Details
Set Aside

NONE

Place of Performance

UNITED STATES

SourceSAM
Documents2
The Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a Combined Synopsis/Solicitation for the procurement of four (4) genomic sequencing systems, specifically the Illumina MiSeq i100 Plus and Illumina DRAGEN™ Bio-IT Platform, or equivalent systems. This acquisition is managed by the FDA Office of Acquisition and Grant Services and is intended to support the FDA’s Human Foods Program (HFP). The primary objective of this procurement is to replace aging sequencing equipment currently in use within the FDA. The new systems will provide high-throughput, cost-effective, and rapid genomic sequencing capabilities that are essential for food safety surveillance, regulatory compliance, and the advancement of novel genomic applications. By upgrading to these systems, the FDA aims to ensure continuity in sequencing methods, maintain compatibility with proprietary flow cells and reagents (or their equivalents), and secure ongoing access to necessary software licenses and manufacturer-supported components. This continuity is critical for the uninterrupted operation of mission-driven projects focused on the timely detection and characterization of foodborne pathogens in regulated products, directly supporting the FDA’s public health mission. The procurement is classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing) and Product Service Code 6640. There are no set-aside restrictions associated with this opportunity, making it open to all qualified vendors. The place of performance is within the United States. Vendors are required to provide systems that are either the specified Illumina models or equivalent solutions that meet the FDA’s stringent requirements for compatibility, performance, and support. The selected systems must integrate seamlessly with existing workflows and support the FDA’s ongoing and future genomic analysis needs. The solicitation remains active, with all terms and conditions unchanged following Amendment 0001, which addressed vendor questions submitted via SAM.gov. Interested parties are encouraged to review the attached amendment document for further clarification. The primary point of contact for this procurement is Sarah Hussain, who can be reached at [email protected]. The opportunity is posted on SAM.gov under Opportunity ID 9d697b1f24994604a6095ae02ee486cb, with a response deadline of June 26, 2026, at 14:06. Contractors considering this opportunity should ensure their proposed solutions align with the FDA’s requirements for system compatibility, support, and continuity of operations, as these elements will remain central throughout the contract lifecycle.